Detailed price information for Tempest Therapeutics Inc (TPST-Q) from The Globe and Mail including charting and trades.
Tempest Therapeutics (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechn
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET. The webcast will be posted to Tempest’s w
This is the newest page. Registered accounts read further back.